Overcoming Obstacles in the Development of Antigen-Specific Immunotherapies for Type 1 Diabetes

Antigen-specific immunotherapy (ASI) holds great promise for type 1 diabetes (T1D). Preclinical success for this approach has been demonstrated in vivo, however, clinical translation is still pending. Reasons explaining the slow progress to approve ASI are complex and span all stages of research and...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Ranjeny, Carballido, José M., Wesley, Johnna D., Ahmed, Simi T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375663/
https://www.ncbi.nlm.nih.gov/pubmed/34421931
http://dx.doi.org/10.3389/fimmu.2021.730414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375663/
https://www.ncbi.nlm.nih.gov/pubmed/34421931
http://dx.doi.org/10.3389/fimmu.2021.730414

Ejemplares similares